All News

Rob Abbott, CEO, ISPOR, highlights how AI is streamlining research and improving patient care while stressing the importance of human oversight.

The AAP diverges from CDC guidelines, advocating for Covid-19 vaccines in young children, igniting debate over vaccine policy and public health integrity.

The disease doesn’t have any FDA approved treatments, leaving families desperate for FDA to approve the treatment.

The global biotherapeutics company announced that it will seek to streamline operations as part of a broader transformation to boost efficiency, refocus on core businesses, and reinvest in high-priority programs.

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing treatment options remain limited.

Monument Therapeutics partners with FNIH to advance MT1988, a promising treatment for cognitive impairment in schizophrenia, through a groundbreaking clinical trial.

Whole genome sequencing market is projected to grow significantly, driven by advancements in technology and personalized medicine, reaching $6.1 billion by 2030.

Rob Abbott, CEO, ISPOR, highlights that the United States excels in areas like cancer screening and advanced medical technology while facing challenges such as rising costs, lack of universal coverage, and health outcomes that lag behind other high-income nations.

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment and ensuring patient safety.

The latest decision will give Vanda the opportunity to have a hearing with FDA over the sNDA’s status.

NIH's new strategy emphasizes transparency, prioritizes urgent health needs, and shifts focus to domestic research and innovative health solutions.

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated significant improvements in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis compared to placebo at 72 weeks.

The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains committed to future treatments.

Papzimeos is the first-and-only approved therapy for adults with recurrent respiratory papillomatosis.

The statement appears to be a response to the President’s recent publication of letters to 17 pharma companies about reducing drug prices.

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and cardiometabolic diseases, aiming for innovative treatments.

Rob Abbott, CEO, ISPOR, highlights how emerging data strategies, advanced technology, and a renewed focus on patient needs are setting the direction for the next era of healthcare worldwide.

The federally created panel was previously disbanded in 1998.

Rob Abbott, CEO, ISPOR, explains how health economics and outcomes research is helping healthcare systems measure the true value of treatments, improve patient outcomes, and address rising drug costs globally.

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with promising RNA interference programs.

The directive calls for building a Strategic Active Pharmaceutical Ingredients Reserve, updating the essential medicines list, and prioritizing US-made APIs.

Fate Therapeutics, Generation Bio, and ORIC Pharmaceuticals join a growing list of companies implementing workforce reductions as they restructure operations, extend cash runways, and focus resources on advancing lead clinical programs amid challenging market conditions.

Connect Biopharma partners with the Jovante Woods Foundation to enhance asthma education and awareness, aiming to prevent acute attacks and save lives.

The new list price will bring the medication in line with other European markets.

Seal Rock Therapeutics joins The Michael J. Fox Foundation's LITE program to help advance research and developments in inhibitors targeting LRRK2 in Parkinsons disease.

Sources say the President’s focus has shifted.

Oikos Fusion offers a nutrient-dense dairy drink designed to support muscle mass and digestive health during weight loss journeys.